Research Article

Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity

Table 2

Clinical, biochemical, and imaging parameters of normal BMI patients with T2DM and visceral adiposity before and after exenatide or humalog Mix25 intervention.

VariablePre-exenatidePost-exenatide valuePre-humalog Mix25Post-humalog Mix25 value
()()()()

BMI (kg/m2)<0.0123.89 (22.65-24.46)23.12 (21.48-23.95)<0.01
Weight (kg)<0.01<0.01
WC (cm)<0.01<0.01
SBP (mmHg)121.5 (117.5-136)128 (117-135.5)0.870.17
DBP (mmHg)78 (75-84)76 (70-81.5)0.100.01
FPG (mmol/L)0.01<0.01
2hPBG (mmol/L)0.0390.47
FINS (mIU/L)0.560.49
HbA1c (%)<0.01<0.01
TC (mmol/L)0.260.82
TG (mmol/L)1.35 (0.84-2.12)1.26 (0.81-1.69)0.131.46 (0.79-2.01)1.09 (0.77-1.6)0.01
AST (IU/L)21 (18-25)22 (18-27)0.280.88
ALT (IU/L)20 (16.5-34.5)22 (16-30.5)0.4322 (18-26)19 (17-24)0.13
Creatinine (μmol/L)0.5253 (44-63)60 (49-66)<0.01
FGF-21 (pg/mL)<0.010.21
SAT (cm2)<0.010.69
VAT (cm2)<0.0176.36 (60.26-96.91)71 (50.24-88.14)<0.01
LFC (%)<0.01<0.01
HOMA-IR<0.010.11
HOMA-β0.630.37
IGI0.333.77 (1.25-6.08)4.27 (1.47-6.81)0.58
Matsuda0.154.54 (3.15-6.01)4.58 (3-7.63)0.78
MBCI0.0454.64 (3.39-6.77)4.04 (2.83-7.38)0.56
HOMA-ISHOMA-β0.010.71
MatsudaMBCI0.09

ALT: glutamic pyruvic transaminase; AST: glutamic oxalacetic transaminase; BMI: body mass index; DBP: diastolic blood pressure; FGF-21: fibroblast growth factor 21; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostatic model assessment of insulin resistance; LFC: liver fat content; MBCI: modified β-cell function; SAT: subcutaneous and visceral adipose tissue; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; VAT: visceral adipose tissue; WC: waist circumference; 2hFBG: 2 h plasma blood glucose. Data are expressed as the or median (interquartile range).